Patents by Inventor Ajit Subramanian
Ajit Subramanian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240126763Abstract: Disclosed herein are techniques for storing, within a database system, metadata that indicates an intended usage (IU). Once created, an IU may be assigned to a column to (a) indicate how the column is intended to be used, and (b) affect how the database server behaves when database operations involve values from the column. The IU assigned to a column supplements, but does not replace, the datatype definition for the column. Each IU may have an IU-bundle. The IU-bundle of an IU indicates how the database server behaves with respect to any column that is assigned the IU. For example, the IU-bundle may indicate constraints that the database server must validate during operations on values from columns assigned to the IU. Techniques are also described for implementing multi-column IUs and flexible IUs.Type: ApplicationFiled: January 19, 2023Publication date: April 18, 2024Inventors: Tirthankar Lahiri, Juan R. Loaiza, Beda Christoph Hammerschmidt, Andrew Witkowski, Sankar Subramanian, Sabina Petride, Ajit Mylavarapu, Gerald Venzl
-
Patent number: 8846032Abstract: The present invention relates to novel MDCK cells which can be to grow viruses, e.g., influenza viruses, in cell culture to higher titer than previously possible. The MDCK cells can be adapted to serum-free culture medium. The present invention further relates to cell culture compositions comprising the MDCK cells and cultivation methods for growing the MDCK cells. The present invention further relates to methods for producing influenza viruses in cell culture using the MDCK cells of the invention.Type: GrantFiled: August 27, 2012Date of Patent: September 30, 2014Assignee: MedImmune, LLCInventors: Jonathan Liu, Richard Schwartz, Mark Thompson, Luis Maranga, Mridul Ghosh, Ajit Subramanian, Simon Sheng-Tsiung Hsu
-
Patent number: 8748174Abstract: The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.Type: GrantFiled: January 20, 2012Date of Patent: June 10, 2014Assignee: MedImmune, LLCInventors: Richard Schwartz, John Michael Berry, Ajit Subramanian, Xiao Shi
-
Publication number: 20130052717Abstract: The present invention relates to novel MDCK cells which can be to grow viruses, e.g., influenza viruses, in cell culture to higher titer than previously possible. The MDCK cells can be adapted to serum-free culture medium. The present invention further relates to cell culture compositions comprising the MDCK cells and cultivation methods for growing the MDCK cells. The present invention further relates to methods for producing influenza viruses in cell culture using the MDCK cells of the invention.Type: ApplicationFiled: August 27, 2012Publication date: February 28, 2013Applicant: MEDIMMUNE, LLCInventors: Jonathan LIU, Richard SCHWARTZ, Mark THOMPSON, Luis Jorge Camilo MARANGA, Simon Sheng-Tsiung HSU, Mridul GHOSH, Ajit SUBRAMANIAN
-
Patent number: 8357376Abstract: The present invention relates to novel MDCK cells which can be to grow viruses, e.g., influenza viruses, in cell culture to higher titer than previously possible. The MDCK cells can be adapted to serum-free culture medium. The present invention further relates to cell culture compositions comprising the MDCK cells and cultivation methods for growing the MDCK cells. The present invention further relates to methods for producing influenza viruses in cell culture using the MDCK cells of the invention.Type: GrantFiled: January 5, 2010Date of Patent: January 22, 2013Assignee: Memimmune, LLCInventors: Jonathan Liu, Richard Schwartz, Mark Thompson, Luis Jorge Camilo Maranga, Simon Sheng-Tsiung Hsu, Mridul Ghosh, Ajit Subramanian
-
Publication number: 20120115206Abstract: The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.Type: ApplicationFiled: January 20, 2012Publication date: May 10, 2012Applicant: Medlmmune WayInventors: Richard Schwartz, John Michael Berry, Ajit Subramanian, Xiao Shi
-
Patent number: 8119388Abstract: The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.Type: GrantFiled: January 13, 2010Date of Patent: February 21, 2012Assignee: Medimmune, LLCInventors: Richard Schwartz, John Michael Berry, Ajit Subramanian, Xiao Shi
-
Publication number: 20100112000Abstract: The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.Type: ApplicationFiled: January 13, 2010Publication date: May 6, 2010Applicant: MEDIMMUNE, LLCInventors: Richard SCHWARTZ, John Michael Berry, Ajit SUBRAMANIAN, Xiao SHI
-
Publication number: 20100112669Abstract: The present invention relates to novel MDCK cells which can be to grow viruses, e.g., influenza viruses, in cell culture to higher titer than previously possible. The MDCK cells can be adapted to serum-free culture medium. The present invention further relates to cell culture compositions comprising the MDCK cells and cultivation methods for growing the MDCK cells. The present invention further relates to methods for producing influenza viruses in cell culture using the MDCK cells of the invention.Type: ApplicationFiled: January 5, 2010Publication date: May 6, 2010Applicant: MEDIMMUNE, LLCInventors: Jonathan LIU, Richard SCHWARTZ, Mark THOMPSON, Luis Jorge Camilo MARANGA, Simon Sheng-Tsiung Hsu, Mridul GHOSH, Ajit SUBRAMANIAN
-
Patent number: 7670837Abstract: The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.Type: GrantFiled: December 16, 2005Date of Patent: March 2, 2010Assignee: Medimmune, LLCInventors: Richard Schwartz, John Michael Berry, Ajit Subramanian, Xiao Shi
-
Publication number: 20080286850Abstract: The present invention relates to novel MDCK cells which can be to grow viruses, e.g., influenza viruses, in cell culture to higher titer than previously possible. The MDCK cells can be adapted to serum-free culture medium. The present invention further relates to cell culture compositions comprising the MDCK cells and cultivation methods for growing the MDCK cells. The present invention further relates to methods for producing influenza viruses in cell culture using the MDCK cells of the invention.Type: ApplicationFiled: September 14, 2007Publication date: November 20, 2008Applicant: MEDIMMUNE VACCINES, INC.Inventors: Jonathan Liu, Richard Schwartz, Mark Thompson, Luis Jorge Camilo Maranga, Simon Sheng-Tsiung Hsu, Mridul Ghosh, Ajit Subramanian
-
Publication number: 20060188977Abstract: The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.Type: ApplicationFiled: December 16, 2005Publication date: August 24, 2006Applicant: MEDIMMUNE VACCINES, INC.Inventors: Richard Schwartz, John Berry, Ajit Subramanian, Xiao Shi